Professor Nicholas Turner is testing if combining a drug palbociclib together with the immunotherapy drug avelumab is safe and could be used to successfully treat a sub-type of triple negative breast cancer.

Professor Nicholas Turner and Dr Alicia Okines will lead a clinical trial of the drug crizotinib for patients with lobular breast cancer that has spread to other parts of the body. This trial, called the ROLO study, could lead to a much-needed new treatment for this type of breast cancer.